Amgen (AMGN) finance VP Matthew Busch sells 1,000 common shares

Rhea-AI Filing Summary

Amgen Inc. vice president sells a small block of shares. Matthew C. Busch, Amgen's VP, Finance & CAO, reported an open-market sale of 1,000 shares of Amgen common stock at a price of $375.79 per share. After this transaction, he directly holds 3,423 shares of Amgen common stock.

The filing notes that these holdings include 60 dividend equivalents granted under Amgen's equity incentive plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen shares on a one-to-one basis as those awards vest.

Insider Trade Summary

Net Seller: 1,000 shares ($375,790)

Net Sell 1 txn

Insider Busch Matthew C.

Role VP, Finance & CAO

Sold 1,000 shs ($376K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$375.79	$376K

Holdings After Transaction: Common Stock — 3,423 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busch Matthew C.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance & CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		S		1,000	D	$375.79	3,423(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Matthew C. Busch	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amgen (AMGN) report for Matthew C. Busch?

Amgen reported that Matthew C. Busch, its VP, Finance & CAO, sold 1,000 shares of common stock in an open-market transaction at $375.79 per share. This Form 4 filing documents the sale and his updated ownership position after the transaction.

How many Amgen (AMGN) shares does Matthew C. Busch own after this Form 4 sale?

After selling 1,000 shares, Matthew C. Busch directly holds 3,423 shares of Amgen common stock. This total includes shares associated with dividend equivalents credited to his unvested restricted stock units under Amgen’s equity incentive plan.

At what price did the Amgen (AMGN) insider shares sell in this Form 4?

The reported transaction shows Matthew C. Busch sold 1,000 Amgen common shares at $375.79 per share. The filing characterizes this as a sale in the open market or a private transaction, reflecting a routine insider trade disclosure.

Who is the insider in the latest Amgen (AMGN) Form 4 filing?

The insider is Matthew C. Busch, who serves as Amgen’s Vice President, Finance & Chief Accounting Officer. The Form 4 reports his sale of 1,000 Amgen common shares and provides details on his remaining equity holdings in the company.

What are the dividend equivalents mentioned in the Amgen (AMGN) Form 4 footnote?

The filing notes that Busch’s holdings include 60 dividend equivalents granted under Amgen’s 2009 Equity Incentive Plan. These are credited to his unvested restricted stock units and convert to Amgen common shares on a one-to-one basis as those awards vest.